Table 3.
Vaccine effectiveness estimates among people with HIV tested for SARS-CoV-2 infection between December 14, 2020 and November 21, 2021, Ontario, Canada.
| Any infection | Symptomatic infection | Severe outcomes (hospitalization/death) | ||||
| Unadjusted | Adjusteda | Unadjusted | Adjusteda | Unadjusted | Adjusteda | |
| VE (95% CI) | VE (95% CI) | VE (95% CI) | VE (95% CI) | VE (95% CI) | VE (95% CI) | |
| Received one dose ≥14 days before index date | 57 (43, 67) | 64 (52, 74) | 51 (5, 75) | 55 (1, 80) | 38 (−19, 67) | 67 (23, 86) |
| Time since first dose (days) | ||||||
| 14–29 | 41 (13, 60) | 51 (27, 68) | 46 (-54, 81) | 38 (-105, 81) | NE | NE |
| 30–59 | 66 (47, 78) | 74 (58, 83) | 56 (-27, 84) | 58 (-36, 87) | NE | NE |
| ≥60 | 62 (34, 79) | 66 (39, 82) | 49 (-70, 85) | 66 (-33, 91) | NE | NE |
| Vaccine product type | ||||||
| ChAdOx1 | 28 (-16, 55) | 39 (-1, 63) | 24 (-163, 78) | 22 (-228, 81) | NE | NE |
| BNT162b2 or mRNA-1273(mRNA vaccines) | 64 (50, 73) | 70 (57, 79) | 57 (7, 80) | 61 (6, 84) | NE | NE |
| Received 2 doses ≥7 days before index date | 86 (81, 89) | 82 (74, 87) | 91 (81, 96) | 94 (82, 98) | 97 (89, 99) | 97 (85, 100) |
| Time since second dose (days) | ||||||
| 7–59 | 88 (80, 93) | 86 (77, 92) | 87 (58, 96) | 92 (69, 98) | NE | NE |
| 60–119 | 86 (78, 91) | 78 (62, 87) | 89 (70, 96) | 93 (74, 98) | NE | NE |
| 120–179 | 84 (72, 91) | 77 (53, 89) | 96 (69, 99) | 98 (73, 100) | NE | NE |
| ≥180 | 79 (34, 93) | 66 (-15, 90) | NE | NE | NE | NE |
| Vaccine product type | ||||||
| ChAdOx1 only | 84 (56, 94) | 77 (34, 92) | NE | NE | NE | NE |
| ≥1 mRNA vaccine dose | 86 (81, 90) | 82 (74, 88) | 90 (79, 95) | 93 (80, 98) | 97 (88, 99) | 97 (83, 100) |
| mRNA only | 86 (81, 90) | 82 (74, 88) | 89 (77, 95) | 93 (79, 98) | 97 (87, 99) | 97 (80, 99) |
| Mixed ChAdOx1 and mRNA doses | 87 (69, 95) | 80 (49, 92) | NE | NE | NE | |
NE, not estimated; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; VE, vaccine effectiveness.
a
Adjusted for age group, sex, public health region, calendar time (restricted cubic spline for week of specimen collection), number of SARS-CoV-2 test episodes in 3 months prior to December 14, 2020, received influenza vaccine in 2019/20 or 2020/21 seasons, number of comorbidities, and neighborhood-level SES indicators. Severe outcomes models adjusted for 4-level region (Greater Toronto Area, East, West, North); any or symptomatic infection models adjusted for public health region.